Leader in UK Biotech

International Health Care Expertise

 

Piper Sandler Ltd. is the leader in biotechnology secondary financings in 2006, based on a listing of the top 10 biotechnology financings, excluding IPOs, for public UK biotech companies in the past five years in BioCentury Magazine. The United Kingdom team served as bookrunner on four of the top five and on two additional secondary financings for UK biotechnology companies. In total, the team is responsible for 80 percent of finance raised through biotechnology follow-on offerings in the UK in 2006.

“We had an extremely successful year serving as the financial advisor for biotechnology clients,” said David Wilson, chief executive officer of Piper Sandler Ltd. “Our health care platform has grown into the industry leader in the UK and we are taking that success and applying it in other industries as we continue to expand our capabilities and expertise.”

The following is a list of the top UK biotechnology secondary financings completed by Piper Sandler Ltd.:

Company Date Type Amount
Vernalis 11/18/05 Placing and Open offer £58.1
Vectura 06/28/06 Placing £45.0
Protherics 12/07/06 Placing and Open offer £38.2
Sinclair 03/31/06 Placing £35.0
Ark Therapeutics 04/27/06 Placing and Open offer £27.1
Antisoma 12/14/06 Placing £26.3